Response to imatinib therapy in adult patients with chronic myeloid leukemia in Saudi population: a single-center study. Issue 4 (April 2015)

• Record Type: Journal Article
• Authors: Alsobhi, Enaam; Abrar, Mohammed Burhan; Abdelaal, Mohammed; Alsaeed, Ahmed; Absi, Ahmed; Alzahrani, Zayed; El-Hemaidi, Ihab; Alshehri, Mohammed Ali; Warsi, Ashraf; Bayashoot, Safaa; Hashem, Heba; Merdad, Anas; Radi, Suhaib; Shiekhi, Hanadi; Al-Amri, Abdulfattah
• Is Part Of: Leukemia & lymphoma. Volume 56:Issue 4(2015:Apr.)
• Page Start: 882
• Page End: 886
• Publication Date: 2015-04
• Subjects: Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2014.935365
• Languages: English
• ISSNs: 1042-8194

Abstract

<abstract> <title>Abstract</title> <p>No study has been published yet in the Arab world regarding response and outcome of imatinib in patients with chronic myeloid leukemia (CML). This study evaluated a total of 122 patients with CML treated with imatinib between 2001 and 2012. Survival, hematologic, cytogenetic and molecular responses and adverse events were assessed. The 5-year overall survival (OS), event free survival (EFS) and progression-free survival (PFS) rates were: 95.4 ± 2.3%, 81.4 ± 4.6% and 90.8 ± 3.2%, respectively. Significant differences in OS (<italic>p</italic> = 0.001), EFS (<italic>p</italic> = 0.001) and PFS (<italic>p</italic> = 0.001) were noted when patients were stratified by cytogenetic response. Survival by Sokal risk groups was not significant (<italic>p</italic> = 0.293). Complete hematologic response was achieved in 94 patients (93.1%), cytogenetic response in 84 (83.2%), major molecular response in 62 (61.4%) and complete molecular response in 34 (33.7%). This article presents the first evidence on the effectiveness of imatinib in patients with CML from Saudi Arabia and highlights similarities and differences in response patterns in published studies.</p> </abstract>